IMMUNODOMINANT PROTEINS AND FRAGMENTS IN MULTIPLE SCLEROSIS Russian patent published in 2024 - IPC A61K38/17 A61K38/44 A61P37/06 

FIELD: medicine; pharmaceutics.

SUBSTANCE: group of inventions relates to antigen-specific immunotherapy. Disclosed is the use of the protein GDP-L-fucose synthase or the protein of the RASGRP family of proteins, its immunodominant fragment, derivative or variant of splicing, or a nucleotide sequence thereof, for the treatment or prevention of multiple sclerosis (MS), where the immunodominant fragment contains from 5 to 50 amino acids, derivative has homology or identity along its entire length with the corresponding part of the reference amino acid sequence of at least 75%. Also disclosed is the use of the protein GDP-L-fucose synthase for the diagnosis of MS, the use of GDP-L-fucose synthase or the protein of the RASGRP family of proteins for human identification, which is suitable for tolerization to autoantigens in MS, a method for producing a chemically bound blood cell, use of a pharmaceutical composition for treating, diagnosing or preventing MS, method for inducing antigen-specific tolerance to self-antigens in a person suffering or at risk of developing MS, a method for identifying a person suitable for tolerance to self-antigens in MS.

EFFECT: group of inventions provides a wider range of products for a specific purpose.

27 cl, 16 dwg, 3 tbl, 15 ex